B7-H3
58 programs · 54 companies
Programs
58
Companies
54
Active Trials
30
Targeting B7-H3
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | NarcolepsyTTR Amyloidosis | |
| Ceviglumide | Roche | NDA/BLA | DLBCLIgAN | |
| SNY-9600 | Sanofi | NDA/BLA | UCMyelofibrosis | |
| SNY-8628 | Sanofi | NDA/BLA | Pompe | |
| SNY-9073 | Sanofi | Phase 2 | CLLWilms | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | HCC | |
| NVO-7872 | Novo Nordisk | NDA/BLA | PTSDNarcolepsy | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | CKDHemophilia A | |
| Datozumab | Regeneron | Phase 1 | RettSchizophrenia | |
| Rimasertib | Exelixis | Phase 3 | RettPancreatic Ca | |
| NUV-283 | Nuvalent | Phase 3 | Parkinson's | |
| Semainavolisib | Krystal Biotech | Phase 2 | LGS | |
| RCU-8819 | Arcus Bio | Preclinical | PompeEpilepsy | |
| Talatuximab | Protagonist | Phase 2 | NMOSD | |
| Gozeosocimab | Altimmune | Preclinical | SLECLL | |
| IPN-3758 | Ipsen | Phase 1 | LGS | |
| 600-1765 | Jiangsu Hengrui | Approved | OCD | |
| Zoribrutinib | Sun Pharma | Preclinical | NBLGS | |
| Tirainavolisib | Dr Reddy's | Approved | Schizophrenia | |
| Mavucapivasertib | Oncopeptides | NDA/BLA | PsA | |
| ECO-IIT-203 | ECOG-ACRIN | Phase 3 | ACC | |
| ECO-IIT-550 | ECOG-ACRIN | Phase 3 | RCC | |
| Niraratamab | Prometheus (Merck) | Phase 2 | MDDGBM | |
| Rilutenlimab | Insilico Medicine | Preclinical | SchizophreniaRSV | |
| Darazasiran | Nuvation Bio | Phase 3 | AngelmanUrothelial Ca | |
| Tirazanubrutinib | Sutro Bio | Approved | CRC | |
| Cevicilimab | Deerfield Mgmt | Phase 3 | DravetALL | |
| Ribozasiran | HTG Molecular | Phase 2/3 | RCCNASH | |
| ELO-7744 | Eloxx Pharma | Phase 2 | CF | |
| AVE-232 | Aveo Pharma (LG Chem) | Phase 1 | HS | |
| Talalucimab | Eliem Therapeutics | Preclinical | SCLC | |
| MNO-1564 | MediciNova | Phase 3 | Hemophilia A | |
| PRO-7290 | Proteus Digital | Phase 2/3 | Ovarian CaFabry | |
| Mavusotorasib | Concert Pharma (Sun) | Phase 1/2 | RA | |
| Niratapinarof | Abbisko | Phase 2/3 | Urothelial CaSCD | |
| 151-9555 | Livzon Pharma | Phase 2/3 | MCLOCD | |
| TRD-3150 | Entrada Ther | Preclinical | BCC | |
| Fixaderotide | Fulcrum Ther | Phase 2/3 | CKDFTD | |
| Voxarapivir | Torrent Pharma | NDA/BLA | CTCLParkinson's | |
| LAU-2489 | Laurus Labs | Phase 2 | HSMS | |
| Talazumab | Natco Pharma | Phase 2/3 | EpilepsyLGS | |
| Datocapivasertib | Hansa Bio | Phase 1/2 | RSVGBM | |
| MRK-6740 | Merck KGaA | Phase 2/3 | ASALS | |
| Zorirasimod | Itamar Medical (Zoll) | Phase 1/2 | Fabry | |
| MAG-6737 | MagForce | Preclinical | NASHCF | |
| CRI-9527 | Cristalia | Phase 3 | UCPBC | |
| CHI-IIT-594 | Chinese PLA General Hosp | NDA/BLA | MDS | |
| ASA-IIT-599 | Asan Medical Center | Phase 2/3 | Angelman | |
| ROY-IIT-152 | Royal Marsden | Phase 1 | HCC | |
| WES-IIT-590 | West China Hosp | Approved | Atopic Derm | |
| CAN-IIT-252 | Cancer Hosp CAMS | Phase 3 | ADHD | |
| RUI-IIT-543 | Ruijin Hospital | Phase 2/3 | Cervical Ca | |
| SIR-IIT-294 | Siriraj Hospital | Approved | NASH | |
| HOS-IIT-848 | Hospital Israelita Einstein | NDA/BLA | MG | |
| Lisozasiran | Frontline BioSciences | NDA/BLA | NMOSD | |
| TEC-1111 | Bio-Techne | Phase 1/2 | LN | |
| Kemamavacamten | Zoetis | Phase 3 | NSCLC | |
| Motanaritide | GNI Group | Approved | PNHRB |